Thrombosis and Thrombocytopenia Syndrome Causing Isolated Symptomatic Carotid Occlusion after Covid-19 Vaccine

Introduction

Thrombosis with thrombocytopenia syndrome (TTS) is a rare adverse event described after vaccination against COVID-19, mainly with nonreplicant adenovirus vector-based vaccines. As of September 9, 2021, reported cases of TTS in Europe and United States account for 8.5 per million doses with ChAdOx1 nCov-19 (AstraZeneca), 3.1 with Ad26.COV2.S (Janssen/Johnson&Johnson), 0.4 with BNT162b2 (Pfizer/BioNtech), and 0.01 with mRNA-1273 (Moderna).[1] [2] [3] Its main features are the presence of acute arterial or venous thrombosis, severe thrombocytopenia, elevated D-dimer, and demonstration of platelet factor 4 (PF4) antibodies in the first 42 days after vaccination.[4] [5] [6] TTS is usually associated to a severe thrombosis profile, affecting multiple organs, most frequently cerebral venous sinus, splanchnic veins, and deep veins with pulmonary embolism. We describe an illustrative case of isolated thrombosis of the carotid artery causing stroke with mildly altered laboratory parameters. The patient provided written informed consent for this report.

Publication History

Received: 09 August 2021

Accepted: 16 October 2021

Accepted Manuscript online:
20 October 2021

Article published online:
29 December 2021

• References

• 1 Centers for Disease Control and Prevention. Selected Adverse Events Reported after COVID-19 Vaccination. Accessed September 9, 2021 at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
• 2 MHRA - Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. Accessed September 9, 2021 at: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adversereactions/coronavirus-vaccine-summary-of-yellow-card-reporting#yellow-card-reports
• 3 European Medicines Agency. COVID-19 vaccine safety update. Accessed September 9, 2021 at: https://www.ema.europa.eu/en/human-regulatory/overview/public-healththreats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#safety-updates-for-authorised-covid-19-vaccines-section
• 4 Chen RT, Black S. Updated Proposed Brighton Collaboration process for developing a standard case definition for study of new clinical syndrome X, as applied to Thrombosis with Thrombocytopenia Syndrome (TTS). Accessed September 9, 2021 at: https://brightoncollaboration.us/wp-content/uploads/2021/05/TTS-Interim-CaseDefinition-v10.16.3-May-23-2021.pdf
• 5 MacNeil JR, Su JR, Broder KR. et al. Updated recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. Morb Mortal Wkly Rep 2021; 70 (17) 651-656
• 6 World Health Organization. Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19). Accessed September 9, 2021 at: https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-TTS-2021.1
• 7 Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021; 384 (23) 2254-2256
• 8 Hursting MJ, Pai PJ, McCracken JE. et al. Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 2010; 134 (05) 774-780
• 9 Schultz NH, Sørvoll IH, Michelsen AE. et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (22) 2124-2130
• 10 Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 (22) 2092-2101
• 11 Sánchez van Kammen M, Heldner MR, Brodard J. et al. Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic. JAMA 2021; 326 (04) 332-338
• 12 Platton S, Bartlett A, MacCallum P. et al. Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost 2021; 19 (08) 2007-2013
• 13 Kenda J, Lovrič D, Škerget M, Milivojević N. Treatment of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia related acute ischemic stroke. J Stroke Cerebrovasc Dis 2021; 30 (11) 106072
• 14 Gabarin N, Patterson S, Pai M. et al. Venous thromboembolism and mild thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Thromb Haemost 2021; DOI: 10.1055/a-1585-6182.
• 15 Charidimou A, Samudrala S, Cervantes-Arslanian AM, Sloan JM, Dasenbrock HH, Daneshmand A. Vaccine-induced immune thrombotic thrombocytopenia with concurrent arterial and venous thrombi following Ad26.COV2.S vaccination. J Stroke Cerebrovasc Dis 2021; 30 (12) 106113
• 16 Scully M, Singh D, Lown R. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021; 384 (23) 2202-2211
• 17 Costentin G, Ozkul-Wermester O, Triquenot A. et al. Acute ischemic stroke revealing ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia: impact on recanalization strategy. J Stroke Cerebrovasc Dis 2021; 30 (09) 105942
• 18 De Michele M, Iacobucci M, Chistolini A. et al. Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia. Nat Commun 2021; 12 (01) 4663
• 19 Bayas A, Menacher M, Christ M, Behrens L, Rank A, Naumann M. Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Lancet 2021; 397 (10285): e11
• 20 Blauenfeldt RA, Kristensen SR, Ernstsen SL, Kristensen CCH, Simonsen CZ, Hvas AM. Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine. J Thromb Haemost 2021; 19 (07) 1771-1775
• 21 Sachs UJ, Cooper N, Czwalinna A. et al. PF4-dependent immunoassays in patients with vaccine-induced immune thrombotic thrombocytopenia: results of an interlaboratory comparison. Thromb Haemost 2021; DOI: 10.1055/a-1535-9002.
• 22 Walter U, Fuchs M, Grossmann A. et al. Adenovirus-vectored COVID-19 vaccine-induced immune thrombosis of carotid artery: a case report. Neurology 2021 DOI: 10.1212/WNL.0000000000012576
• 23 Pavord S, Scully M, Hunt BJ. et al. Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med 2021; 385: 1680-1689
• 24 Fridman S, Lownie SP, Mandzia J. Diagnosis and management of carotid free-floating thrombus: a systematic literature review. Int J Stroke 2019; 14 (03) 247-256
• 25 Zazzeron L, Rosovsky RP, Bittner EA, Chang MG. Comparison of published guidelines for the diagnosis and the management of vaccine-induced immune thrombotic thrombocytopenia. Crit Care Explor 2021; 3 (09) e0519